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Objective: Lipocalin-2 (LCN2) is a recently characterized adipokine that is upregulated in chondrocytes
treated with pro-inﬂammatory mediators and in the synovial ﬂuid of osteoarthritis (OA) patients. Here,
we explored the in vivo functions of LCN2 in OA cartilage destruction in mice.
Methods: The expression levels of LCN2 were determined at the mRNA and protein levels in primary
cultured mouse chondrocytes and in human and mouse OA cartilage. Experimental OA was induced in
wild-type (WT) or Lcn2-knockout (KO) mice by destabilization of the medial meniscus (DMM) or intra-
articular (IA) injection of adenoviruses expressing hypoxia-inducible factor (HIF)-2a (Ad-Epas1), ZIP8
(Ad-Zip8), or LCN2 (Ad-Lcn2). The effect of LCN2 overexpression on the cartilage of WT mice was
examined by IA injection of Ad-Lcn2.
Results: LCN2 mRNA levels in chondrocytes were markedly increased by the pro-inﬂammatory cyto-
kines, interleukin (IL)-1b and tumor necrosis factor-a (TNF-a), and by previously identiﬁed catabolic
regulators of OA, such as HIF-2a and components of the zinc-ZIP8-MTF1 axis. LCN2 protein levels were
also markedly increased in human OA cartilage and cartilage from various experimental mouse models of
OA. However, overexpression of LCN2 in chondrocytes did not modulate the expression of cartilage
matrix molecules or matrix-degrading enzymes. Furthermore, LCN2 overexpression in mouse cartilage
via IA injection of Ad-Lcn2 did not cause OA pathogenesis, and Lcn2 KO mice showed no alteration in
DMM-induced OA cartilage destruction.
Conclusions: Our observations collectively suggest that upregulation of LCN2 in OA cartilage is not suf-
ﬁcient or necessary for OA cartilage destruction in mice.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society
International. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
During osteoarthritis (OA) pathogenesis, chondrocytes produce
matrix-degrading enzymes, including matrix metalloproteinase
(MMP) 3, MMP13, and ADAMTS5, and cease synthesizing cartilage
matrix molecules, such as type II collagen and aggrecan1. Many
soluble mediators have been reported to regulate these processes
in chondrocytes. For instance, hypoxia-inducible factor (HIF)-2a,
which is transcriptionally upregulated in OA chondrocytes in
response to mechanical stress and pro-inﬂammatory cytokines,
increases the expression of matrix-degrading enzymes2,3.o: J.-S. Chun, School of Life
gy, Buk-Gu, Gwangju 61005,
er Ltd on behalf of Osteoarthritis R
d/4.0/).
Chun J-S, Upregulation of lipo
ilage (2016), http://dx.doi.orgUpregulation of the zinc importer, ZIP8, and its inﬂux of zinc into
chondrocytes also induces matrix-degrading enzymes and re-
presses cartilage matrix synthesis4,5. Many studies have revealed
that adipokines, which are mainly produced in white adipose tis-
sue, are also produced in chondrocytes, where they act as soluble
mediators of OA pathogenesis by regulating inﬂammation and
cartilage destruction6,7. For example, visfatin causes OA cartilage
destruction inmice by upregulatingMMP3, MMP12, andMMP13 in
chondrocytes3.
Lipocalin-2 (LCN2; also known as neutrophil gelatinase-
associated lipocalin, or NGAL) is a secreted glycoprotein that has
been characterized as an adipokine. It binds to small substances,
such as steroids and lipopolysaccharide (LPS), to mediate various
physiological and pathophysiological processes, including meta-
bolic homeostasis, apoptosis, and immune responses6. Although
white adipose tissue is the main source of LCN26, the protein is
also expressed in articular chondrocytes. Studies have shown thatesearch Society International. This is an open access article under the CC BY-NC-ND
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1b, adipokines (leptin and adiponectin), LPS, and dexametha-
sone6,8,9. In addition, a complex comprising LCN2 and MMP9 is
reportedly enriched in the synovial ﬂuid of human OA knees,
where it contributes to matrix degradation10. Thus, LCN2 is
believed to play a signiﬁcant functional role in OA cartilage11 and
may hold promise as a biomarker for cartilage degradation in
arthritic disease12.
Although LCN2 is believed to be associated with OA
pathogenesis, however, no previous study has examined its effects
on catabolic or anabolic genes during OA pathogenesis, and its
in vivo functions in OA pathogenesis are unknown. Here, we
examined the in vivo functions of LCN2 in mouse models of OA
cartilage destruction. We report that although LCN2 is upregulated
in OA cartilage, its upregulation is not sufﬁcient or necessary for
post-traumatic OA cartilage destruction in mice.
Materials and methods
Human OA cartilage and experimental OA in mice
Human OA cartilage was sourced from individuals undergoing
arthroplasty, as described previously2e5,13. The Review Board of
the Wonkwang University Hospital approved the use of these
materials, and all individuals provided full written informed
consent before the operative procedure. Male mice (C57BL/6)
were used for experimental OA studies. Lcn2-knockout (KO) mice
were obtained from Jackson Laboratory. All experiments were
approved by the Gwangju Institute of Science and Technology
Animal Care and Use Committee. Experimental OA was induced
by destabilization of the medial meniscus (DMM) surgery or
intra-articular (IA) injection of adenoviruses (once weekly for 3
weeks, 1  109 plaque forming units) expressing HIF-2a (Ad-
Epas1), ZIP8 (Ad-Zip8), or LCN2 (Ad-Lcn2) (Vector Biolabs), as
described previously2e5,13. At 8 weeks and 10 weeks after DMM
surgery or 3 weeks and 8 weeks after the ﬁrst IA injection, mice
were sacriﬁced, and histological and biochemical analyses were
performed. Cartilage destruction in mice was examined using
alcian blue or safranin-O staining, and scored using the Osteo-
arthritis Research Society International (OARSI) grading sys-
tem2e5,13. Cartilage sections were immunostained for HIF-2a
(ab8365; Abcam), ZIP8 (sc-133415; Santa Cruz Biotechnology),
and LCN2 (ab63929; Abcam).
Chondrocytes, adenoviral infection, and biochemical analysis
Chondrocytes were isolated from the femoral condyles and
tibial plateaus of mice, and maintained as described pre-
viously2e5,13. On day 2 of culture, chondrocytes were treated as
indicated or infected with adenoviruses at the indicated multi-
plicity of infection (MOI). Mouse LCN2 mRNAs were detected by
reverse-transcription-polymerase chain reaction (RT-PCR) and
measured by quantitative RT-PCR (qRT-PCR) using speciﬁc
primers (sense 50-AGACTTCCGGAGCGATCAGT-30; antisense, 50-
ACTGGTTGTAGTCCGTGGTG-30). The primer sequences for the
other indicated transcripts were as described previously2e5,13.
LCN2 protein levels were detected by Western blotting (ab63929;
Abcam).
Statistical analysis
The n number indicated in each ﬁgure corresponds to the
number of statistically independent observations or the number
of mice used. Normal distribution of the data was conﬁrmedPlease cite this article in press as: Choi W-S, Chun J-S, Upregulation of lipo
destruction in mice, Osteoarthritis and Cartilage (2016), http://dx.doi.orgusing the ShapiroeWilk test. For all qRT-PCR data, two-way
analysis of variance (ANOVA) with post-hoc tests was used. Data
quantiﬁed on an ordinal grading system, such as the OARSI grade,
were analyzed using non-parametric ManneWhitney U test. All
data are presented as the mean and the 95% conﬁdence intervals
(CIs).
Results
LCN2 is upregulated in OA chondrocytes and cartilage
RT-PCR and qRT-PCR analyses revealed that mRNA levels of
LCN2were markedly increased in primary cultured mouse articular
chondrocytes treated with IL-1b, tumor necrosis factor (TNF)-a,
HIF-2a (encoded by Epas1)2, and ZIP84 [Fig. 1(A) and (B)]. The
protein levels of LCN2 were also markedly elevated in OA-affected
regions of human cartilage, comparedwith undamaged areas of the
same sample [Fig. 1(C)], and in OA cartilage from mice subjected to
DMM surgery or IA injection of Ad-Epas1 or Ad-Zip8 [Fig. 1(D)].
These results suggest that LCN2 expression in chondrocytes might
contribute to the pathogenesis of OA in mouse models of this
disease.
Upregulation of LCN2 is not sufﬁcient or necessary for OA cartilage
destruction in mice
Based on the above results, we assessed whether LCN2 could
regulate OA cartilage destruction. We ﬁrst examined the ability of
LCN2 to regulate the expression levels of matrix-degrading en-
zymes and cartilage matrix molecules in primary cultured mouse
articular chondrocytes. However, the Ad-Lcn2-induced over-
expression of LCN2 in chondrocytes did not alter the expression
levels of catabolic matrix-degrading enzymes (e.g., MMP3, MMP13,
and ADAMTS5) or anabolic cartilage matrix molecules (e.g., type II
collagen or aggrecan) [Fig. 2(A)].
Next, we performed IA injection of Ad-Lcn2 into mouse knee
joints and examined the in vivo role of LCN2 in OA pathogenesis at 3
weeks or 8 weeks after IA injection. Consistent with our previous
demonstration that this method could yield effective gene deliv-
ery2e5,13, Ad-Lcn2 injection caused LCN2 to be overexpressed in the
cartilage, meniscus and synovium of injected joints [Fig. 2(B)].
However, cartilage destruction or synovial inﬂammation was not
observed at both 3 weeks and 8 weeks after IA injection [Fig. 2(C)
and (D)], indicating that LCN2 overexpression is not sufﬁcient to
initiate OA pathogenesis in this system.
Finally, we examined whether LCN2 expression is necessary
for OA pathogenesis. However, we found that the siRNA-
mediated knockdown of LCN2 in primary cultured mouse
chondrocytes did not affect the IL-1b-induced upregulation of
matrix-degrading enzymes or the concurrent downregulation of
cartilage matrix molecules [Fig. 2(E)]. Similarly, knockdown of
LCN2 did not affect HIF-2a- or ZIP8-modulated expression of
catabolic and anabolic factors in chondrocytes [Fig. 2(E)].
Furthermore, WT and Lcn2-KO mice exhibited similar degrees of
cartilage destruction and other manifestations of OA (e.g.,
osteophyte formation and subchondral bone sclerosis) at 8
weeks [Fig. 2(F) and (G)] or 10 weeks (data not shown) after
DMM surgery. These results collectively suggest that LCN2 is not
necessary for post-traumatic OA in mice.
Discussion
Several studies have suggested that LCN2 may be associated
with OA pathogenesis. For example, pro-inﬂammatory mediatorscalin-2 (LCN2) in osteoarthritic cartilage is not necessary for cartilage
/10.1016/j.joca.2016.07.009
Fig. 1. LCN2 is upregulated in OA chondrocytes and cartilage. (A and B) LCN2 mRNA levels were detected by RT-PCR (A) and quantiﬁed by qRT-PCR (B) in chondrocytes stimulated
with IL-1b (n ¼ 5) and TNF-a (n ¼ 5) or infected with the indicated MOIs of Ad-Epas1 (n ¼ 7) and Ad-Zip8 (n ¼ 7). (C) Representative images of alcian blue staining and im-
munostaining of LCN2 in damaged and undamaged regions of human OA cartilage (n ¼ 6). (D) Representative images of safranin-O staining and immunostaining of LCN2 in cartilage
sections from mice subjected to sham operation (n ¼ 4), DMM surgery (n ¼ 10), or IA injection with 1  109 plaque forming units of Ad-C (n ¼ 10), Ad-Epas1 (n ¼ 10) or Ad-Zip8
(n ¼ 10). Values are the means ±95% CI. Scale bar: 50 mm.
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expression in chondrocytes6,8,9, and upregulation of LCN2 was
found in synovial ﬂuid from human OA patients10. However, the
cause-and-effect relationship between LCN2 and OA pathogenesis
was unknown, as was the function of LCN2 in OA pathogenesis
in vivo. Here, we report that HIF-2a and ZIP8, two recently identi-
ﬁed catabolic regulators of OA2,4, also upregulate LCN2 in chon-
drocytes. Although LCN2 expression is increased in OA
chondrocytes and cartilage, however, we found that LCN2 alone is
neither sufﬁcient nor necessary for post-traumatic OA cartilage
destruction in mice.
We ﬁrst employed IA injection of Ad-Lcn2 to examine the in vivo
function of LCN2. We previously used this approach to identify
numerous catabolic regulators of OA, including HIF-2a, NAMPT,
ZIP8, MTF1, metallothionein 2, and lysyl oxidase2e5,13. Here, we
found that ectopic expression of LCN2 alone in the knee joint tis-
sues of mice was not sufﬁcient to cause cartilage destruction. This is
consistent with our ﬁnding that overexpression of LCN2 in chon-
drocytes failed to alter the expression of matrix-degrading en-
zymes in vitro. Although LCN2 post-translationally regulates MMP9
activity10, we found that it did not alter the chondrocytic expres-
sion levels of MMP3, MMP13 or ADAMTS5, all of which play crucialPlease cite this article in press as: Choi W-S, Chun J-S, Upregulation of lipo
destruction in mice, Osteoarthritis and Cartilage (2016), http://dx.doi.orgroles in cartilage destruction1. Moreover, we found that KO of Lcn2
in mice did not alter OA in the DMM mouse model, indicating that
the upregulation of LCN2 in OA cartilage is not a prerequisite for
cartilage destruction. We examined cartilage destruction at 8 or
10 weeks after DMM surgery. Although it is possible that LCN2
may modify disease severity in later stages, we have previously
found that KO of HIF-2a or ZIP8 effectively blocked cartilage
destruction at 8 weeks after DMM surgery2,4. Consistent with our
in vivo results, LCN2 knockdown in chondrocytes did not alter the
IL-1b-, HIF-2a-, or ZIP8-induced upregulations of MMP3, MMP13,
or ADAMTS5.
The expression of LCN2 is altered in several inﬂammatory
diseases, and this factor has been proposed as a potential
biomarker for various diseases, including acute kidney injury,
lupus nephritis, and obesity-related metabolic diseases6. Although
our results indicate that LCN2 is not a catabolic regulator of OA
pathogenesis, its expression is upregulated in chondrocytes stim-
ulated with various OA-causing catabolic regulators, and in the OA
cartilage of human patients and various experimental mouse
models of OA. This is consistent with the notion that LCN2 could
be a possible biomarker for cartilage degradation in arthritic
disease12.calin-2 (LCN2) in osteoarthritic cartilage is not necessary for cartilage
/10.1016/j.joca.2016.07.009
Fig. 2. Upregulation of LCN2 is not sufﬁcient or necessary for OA cartilage destruction in mice. (A) Protein and mRNA levels of LCN2 in chondrocytes infected with Ad-C (800 MOI) or
the indicated MOI of Ad-Lcn2 (n ¼ 6). (BeD) Mice were IA-injected with Ad-C or Ad-Lcn2 (1  109 PFU, once per week for 3 weeks), and sacriﬁced 3 or 8 weeks after the ﬁrst
injection. Representative images of immunohistochemical staining for LCN2 in the joint tissues (B; n ¼ 10). OARSI grade and synovial inﬂammation (C; n ¼ 10). Cartilage destruction
and synovitis detected by safranin-O/hematoxylin staining (D; n ¼ 10). (E) RT-PCR analysis of the indicated mRNAs in chondrocytes transfected with or without the Lcn2 siRNA and
further treated with IL-1b (left; n ¼ 5) or infected with 800 MOI of Ad-Epas1 (middle; n ¼ 5) or Ad-Zip8 (right; n ¼ 5). (F) Genotype and LCN2 mRNA levels in chondrocytes of WT
and Lcn2 KO mice. (G) Cartilage sections from sham- and DMM-operated WT (n ¼ 10) and Lcn2-KO mice (n ¼ 10) were stained with safranin-O, and cartilage destruction was
quantiﬁed by OARSI grade. Values are the means ±95% CI. Scale bar: 50 mm.
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